# Type III Dysbetalipoproteinemia

> **NCT00214604** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 30 (—)

## Conditions studied

- Hyperlipoproteinemia Type III

## Interventions

- **DRUG:** Rosuvastatin
- **DRUG:** rosuvastatin
- **DRUG:** pravastatin

## Key facts

- **NCT ID:** NCT00214604
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2007-02
- **Final completion:** 2007-02
- **Target enrollment:** 30 (—)
- **Last updated:** 2010-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00214604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00214604, "Type III Dysbetalipoproteinemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00214604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*